Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Soluble terminal complement components in human myasthenia gravis

R J Barohn1, R L Brey

  • 1Department of Medicine, University of Texas Health Science Center at San Antonio 78284-7883.

Clinical Neurology and Neurosurgery
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design.

Neurology·2011
Same author

Antiphospholipid antibodies and the brain: a consensus report.

Lupus·2011
Same author

International consensus for a definition of disease flare in lupus.

Lupus·2010
Same author

Antiphospholipid syndrome and the brain in pediatric and adult patients.

Lupus·2010
Same author

The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.

Brain : a journal of neurology·2009
Same author

Inclusion body myositis: old and new concepts.

Journal of neurology, neurosurgery, and psychiatry·2009
Same journal

Clinical response after cerebrospinal fluid shunting in complex versus pure idiopathic normal pressure hydrocephalus: A systematic review and meta-analysis.

Clinical neurology and neurosurgery·2026
Same journal

Preoperative sleep medication use and outcomes following lumbar spine surgery.

Clinical neurology and neurosurgery·2026
Same journal

Long-term real-world outcomes and device management of intrathecal drug delivery systems: A 16-year single-center experience with a primary focus on baclofen therapy.

Clinical neurology and neurosurgery·2026
Same journal

Trends and safety of outpatient versus inpatient lumbar interbody fusion - A national cohort study.

Clinical neurology and neurosurgery·2026
Same journal

A case report on αIN antibody-mediated paraneoplastic cerebellar ataxia.

Clinical neurology and neurosurgery·2026
Same journal

Early prediction of prolonged mechanical ventilation in invasively ventilated patients with subarachnoid hemorrhage: A MIMIC-IV prediction model study.

Clinical neurology and neurosurgery·2026
See all related articles

Elevated terminal complement complex (SC5b-9) in myasthenia gravis (MG) patients suggests complement plays a role in muscle damage. However, plasma SC5b-9 levels don't consistently track disease activity.

Area of Science:

  • Immunology
  • Neurology
  • Complement System

Background:

  • Myasthenia gravis (MG) involves acetylcholine receptor (AChR) loss and neuromuscular junction (NMJ) damage.
  • Complement-mediated muscle membrane injury is implicated in MG pathogenesis, evidenced by C9 at the NMJ.
  • The terminal complement complex (SC5b-9) is a marker of complement activation.

Purpose of the Study:

  • To investigate the presence and correlation of plasma SC5b-9 levels with disease activity in myasthenia gravis patients.
  • To assess the role of terminal complement components in the pathogenesis of human MG.

Main Methods:

  • Plasma samples from 31 MG patients and healthy controls were analyzed using ELISA for SC5b-9.
  • Longitudinal sampling was performed for 8 patients to track changes over time.

Related Experiment Videos

  • SC5b-9 levels were correlated with clinical disease severity and AChR antibody levels.

    • Main Results:

    • Abnormal SC5b-9 elevations were detected in 58% of MG patients (18 of 31) at one or more time points.
    • In some patients, increased SC5b-9 values correlated with clinical deterioration.
    • No clear distinction was observed between MG severity or AChR antibody levels and SC5b-9 values across the patient group.

    Conclusions:

    • Elevated plasma SC5b-9 supports the role of complement-mediated muscle membrane damage in MG pathogenesis.
    • Plasma SC5b-9 levels, as measured by ELISA, do not consistently correlate with disease activity in all MG patients.
    • Further research is needed to fully elucidate the utility of SC5b-9 as a biomarker in MG.